SCHEMBL707786

SCHEMBL707786

C(C=Cc1cnc2ccccc2n1)=Cc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 2/20 0.50
PDGFRA P16234 2/20 0.50
MAOB P27338 1/20 0.50
PAX8 Q06710 1/20 0.48
RAB9A P51151 6/20 0.47
NPC1 O15118 4/20 0.47
KDM4E B2RXH2 4/20 0.47
LMNA P02545 3/20 0.47
PKM P14618 1/20 0.47
DHFR P00374 1/20 0.44
POLB P06746 2/20 0.42
MAPT P10636 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 6/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
GRM4 Q14833 1/20 0.41
HPGD P15428 3/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PDE10A Q9Y233 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL707785 1.00 PDGFRB (0.50) PDGFRBPDGFRAMAOBPAX8RAB9A
SCHEMBL711460 0.89 KDM4E (0.59) PDGFRBPDGFRAPAX8RAB9ANPC1
SCHEMBL711461 0.89 KDM4E (0.59) PDGFRBPDGFRAPAX8RAB9ANPC1
SCHEMBL12923109 0.83 PAX8 (0.63) PDGFRBPDGFRAPAX8RAB9ANPC1
SCHEMBL6852180 0.80 RAB9A (0.48) PAX8RAB9ANPC1KDM4ELMNA
SCHEMBL6852174 0.80 RAB9A (0.48) PAX8RAB9ANPC1KDM4ELMNA
SCHEMBL708674 0.79 PAX8 (0.56) PDGFRBPDGFRAPAX8RAB9ANPC1
SCHEMBL708673 0.79 PAX8 (0.56) PDGFRBPDGFRAPAX8RAB9ANPC1
SCHEMBL714135 0.76 RAB9A (0.79) MAOBRAB9ANPC1KDM4ELMNA
SCHEMBL714134 0.76 RAB9A (0.79) MAOBRAB9ANPC1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124625-B2 enhancing the expression of apoAI; prevention or therapy of dislipidemia SHIONOGI & CO., LTD. (JP) 2012-02-28 US disclosed
US-8053445-B2 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2011-11-08 US disclosed
US-20090036457-A1 Utilities of olefin derivatives YAMAMORI TERUO 2009-02-05 US disclosed
US-20040242615-A1 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242615-A1 Utilities of olefin derivatives APOL1, NR1H2, APOB PDGFRB 2744/4885PDGFRA 3181/4885MAOB 387/4885
US-20090036457-A1 Utilities of olefin derivatives APOL1, APOB, NR1H2 PDGFRB 3680/4885PDGFRA 4261/4885MAOB 377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.